[1]
|
http://www.cancer.gov/dictionary?cdrid=546597
|
[2]
|
R. S. Kerbel and B. A. Kamen, “The Anti-Angiogenic Basis of Metronomic Chemotherapy,” Nature, Vol. 4, No. 6, 2004, pp. 423-436.
|
[3]
|
D. Hanahan, G. Bergers and E. Bergsland, “Less is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice,” Journal of Clinical Investigation, Vol. 105, No. 8, 2000, pp. 1045-1047.
doi:10.1172/JCI9872
|
[4]
|
S. Man, G. Bocci, G. Francia, S. K. Green, S. Jothy, D. Hanahan, et al., “Antitumor Effects in Mice of Low-Dose (Metronomic) Cyclophosphamide Administered Continuously through the Drinking Water,” Cancer Research, Vol. 62, No. 10, 2002, pp. 2731-2735.
|
[5]
|
Y. Hamano, H. Sugimoto, M. A. Soubasakos, M. Kieran, B. R. Olsen, J. Lawler, et al., “Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression,” Cancer Research, Vol. 64, No. 5, 2004, p. 1570.
doi:10.1158/0008-5472.CAN-03-3126
|
[6]
|
J. E. Damber, C. Vallbo, P. Albertsson, B. Lennernas and K. Norrby, “The Anti-Tumour Effect of Low-Dose Continuous Chemotherapy May Partly Be Mediated by Thrombospondin,” Cancer Chemotherapy and Pharmacology, Vol. 58, No. 3, 2006, pp. 354-360.
doi:10.1007/s00280-005-0163-8
|
[7]
|
M. E. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom and H. Sabzevari, “Inhibition of CD4(_)25_T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide,” Blood, Vol. 105, No. 7, 2005, pp. 2862-2868.
doi:10.1182/blood-2004-06-2410
|
[8]
|
J. Mayer, M. Krejcí, M. Doubek, Z. Pospísil, Y. Brychtová, et al., “Pulse Cyclophosphamide for Corticoid -Refractory Graft-Versus-Host Disease,” Bone Marrow Transplantation, Vol. 35, No. 7, 2005, pp. 699-705.
doi:10.1038/sj.bmt.1704829
|
[9]
|
A. Reiner, T. Gernsheimer and S. J. Slichter, “Pulse Cyclophosphamide Therapy for Refractory Autoimmune Thrombocytopenic Purpura,” Blood, Vol. 85, No. 2, 1995, pp. 351-358.
|
[10]
|
N. Penel, A. Adenis and G. Bocci, “Cyclophosphamide-Based Metronomic Chemotherapy: After 10 Years of Experience, Where Do We Stand and Where Are We Going?” Critical Reviews in Oncology/Hematology, Vol. 82, No. 1, 2011, pp. 40-50.
|
[11]
|
M. Colleoni, A. Rocca, M. T. Sandri, et al., “Low-Dose Oral Methotrexate and Cyclophosphamide in Metastatic Breast Cancer: Antitumor Activity and Correlation with Vascular Endothelial Growth Factor Levels,” Annals of Oncology, Vol. 13, No. 1, 2002, pp. 73-80.
doi:10.1093/annonc/mdf013
|
[12]
|
G. Bocci, M. Tuccori, U. Emmenegger, V. Liguori, A. Falcone, R. S. Kerbel, and M. Del Tacca, “Cyclophosphamide-Methotrexate ‘Metronomic’ Chemotherapy for the Palliative Treatment of Metastatic Breast Cancer. A Comparative Pharmacoeconomic Evaluation,” Annals of Oncology, Vol. 16, No. 8, 2005, pp. 1243-1252.
doi:10.1093/annonc/mdi240
|
[13]
|
D. Raghavan, K. Cox, B. S. Pearson, et al., “Oral Cyclophosphamide for the Management of Hormone-Refractory Prostate Cancer,” British Journal of Urology, Vol. 72, No. 5, 1993, pp. 625-628.
doi:10.1111/j.1464-410X.1993.tb16222.x
|
[14]
|
R. Lord, S. Nair, A. Schache, J. Spicer, N. Somaihah, V. Khoo and H. Pandha, “Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study,” Journal of Urology, Vol. 177, No. 6, 2007, pp. 2136-2140.
doi:10.1016/j.juro.2007.01.143
|
[15]
|
T. Nelius, K. Rinard and S. Filleur, “Oral/Metronomic Cyclophosphamide-Based Chemotherapy as Option for Patients with Castration-Refractory Prostate Cancer: Review of the Literature,” Cancer Treatment Reviews, Vol. 37, No. 6, 2011, pp. 444-455.
doi:10.1016/j.ctrv.2010.12.006
|
[16]
|
G. Di Lorenzo, V. Montesarchio, R. Autorino, T. Bellelli, N. Longo, et al., “Phase 1/2 Study of Intravenous Paclitaxel and Oral Cyclophosphamide in Pretreated Metastatic Urothelial Bladder Cancer Patients,” Cancer, Vol. 115, No. 3, 2009, pp. 517-523. doi:10.1002/cncr.24055
|
[17]
|
T. R. Fleming, “Objective Response Rate as a Surrogate End Point: A Commentary,” Journal of Clinical Oncology, Vol. 23, No. 22, 2005, pp. 4845-4846.
doi:10.1200/JCO.2005.92.008
|
[18]
|
T. R. Fleming, “Surrogate End Points and FDA’s Accelerated Approval Process,” Health Affairs, Vol. 24, No. 1, 2005, pp. 67-78. doi:10.1377/hlthaff.24.1.67
|
[19]
|
F. S. Hodi, S. J. O’Day, D. F. McDermott, R. W. Weber, J. A. Sosman, et al., “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,” The New England Journal of Medicine, Vol. 363, No. 8, 2010, pp. 711-723.
doi:10.1056/NEJMoa1003466
|
[20]
|
N. Mauritzson, M. Albin, L. Rylander, R. Billstr?m, T. Ahlgren, et al., “Pooled Analysis of Clinical and Cytogenetic Features in Treatment-Related and de Novo Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Based on a Consecutive Series of 761 Patients Analyzed 1876-1993 and on 5098 Unselected Cases Reported in the Literature 1974-2001,” Leukemia, Vol. 16, No. 12, 2002, pp. 2366-2378. doi:10.1038/sj.leu.2402713
|
[21]
|
Y. Xu, H. Wang, S. Zhou, M. Yu, X. Wang, et al., “Risk of Second Malignant Neoplasms after Cyclophosphamide-Based Chemotherapy with or without Radiotherapy for Non-Hodgkin’s Lymphoma,” Leukemia & Lymphoma, 26 November 2012, [Epub ahead of print].
doi:10.3109/10428194.2012.743657
|